X-linked adrenoleukodystrophy: The Saudi experience

Saudi Medical Journal

Volumn 21, Issue 1, 2000, Pages 61-71

  Al Essa, Mohammed A ^a   Sakati, Nadia A ^a   Bakheet, Siema M ^a   Patay, Zoltan J ^a   Dabbagh, Omar ^a   Chaves Carballo, Enrique ^a   Ozand, Pinar T ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Biochemical; Clinical; Neurophysiological findings; Neuroradiological; X linked adrenoleukodystrophy

Indexed keywords

ADOLESCENT; ADRENOLEUKODYSTROPHY; ARTICLE; BEHAVIOR DISORDER; BLOOD; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENETIC VARIABILITY; GENETICS; HEARING DISORDER; HUMAN; LEARNING DISORDER; MENTAL DEFICIENCY; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIGREE; PHENOTYPE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SAUDI ARABIA; SEIZURE; SURVIVAL; VISUAL DISORDER;

ADOLESCENT; ADRENOLEUKODYSTROPHY; CHILD; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; HEARING DISORDERS; HUMANS; LEARNING DISORDERS; MAGNETIC RESONANCE IMAGING; MENTAL RETARDATION; PEDIGREE; PHENOTYPE; RETROSPECTIVE STUDIES; SAUDI ARABIA; SEIZURES; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; VARIATION (GENETICS); VISION DISORDERS;

EID: 0033767088     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Hashmi M, Stanley W, Singh I. Lignoceroyl-CoASH ligase: enzyme defect in fatty acid beta-oxidation system in X-linked childhood adrenoleukodystrophy. FEBS Let 1986; 196: 247-250.
2. Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci USA 1988; 85: 7647-7651.
3. Lazo O, Contreras M, Bhushan A, Stanley W, Singh I. Adrenoleukodystrophy. impaired oxidation of fatty acids due to peroxisomal lignoceroyl-CoA ligase deficiency. Arch Biochem Biophys 1989; 270: 722-728.
4. Poggi-Travert F, Fournier B, Poll-The BT, Saudubray JM. Clinical approach to inherited peroxisomal disorders. J Inherit Metab Dis 1995; 18: 1-18.
5. Moser HW, Smith KD, Moser AB X-Linked Adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds The Metabolic and Molecular Bases of Inherited Disease, 7th ed. New York: McGraw Hill, 1995: 2325-2349.
6. Moser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361: 72-730.
7. Caruso U, Fowler B, Erceg M, Romano C. Determination of very-long-chain fatty acids in plasma by a simplified gas chromatographic-mass spectrometric procedure. J Chromatogr 1991; 562: 147-152.
8. Vallance H, Applegarth D. An improved method for quantification of very long chain fatty acids in plasma. Clin Biochem 1994; 27: 183-186.
9. Hajra AK, Bishop JE. Glycerolipid biosynthesis in peroxisomes via the acyl dihydroacetone phosphate pathway. Ann N Y Acad Sci 1982; 386: 170-182.
10. Brismar J. CT and MRI of the brain in inherited neurometabolic disorders. J Child Neurol 1992; 7 (suppl): 112-131.
11. Assessment: Positron Emission Tomography. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1991; 41: 163-167.
12. Stigsby B, Yarworth SM, Rahbeeni Z, Dabbagh O, de Gier Munk C, Abdo N, et al. Neurophysiologic correlates of organic acidemias: a survey of 107 patients. Brain Dev 1994; 16 (suppl): 125-144.
13. Siemerling E, Creutzfeldt HG. Bronzenkrankenheit und sklerosierende Encephalomyelitis (diffuse sclerosis). Arch Psychiatr Nervenkr 1923; 68: 217-244.
14. Fanconi VA, Prader A, Isler W, Luthy F, Siebenmann R. Morbus Addison mit Hirnsklerose im Kindersalter: Ein heridit res Syndrom mit X-chromosomaler Verebung? Helv Paediatr Acta 1963; 18: 480-501.
15. Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976; 26: 851-860.
16. Moser HW, Naidu S, Kumar AJ, Rosenbaum AE. The adrenoleukodystrophies. Crit Rev Neurobiol 1987; 3: 29-88.
17. Aubourg P, Chaussain JL, Dulac O, Arthuis M. Adrenoleukodystrophy in children. Apropos of 20 cases. Arch Fr Pediatr 1982; 39: 663-669.
18. Moser HW. Adrenoleukodystrophy: Natural history, treatment and outcome. J Inherit Metab Dis 1995; 18: 435-447.
19. Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis 1992; 15: 645-664.
20. Coria F, Garcia-Viejo MA, Delgado JA. Duarte J, Claveria LE, Giros M, et al. Diagnosis of X-adrenoleucodystrophy phenotypic variants. Acta Neurol Scand 1993; 87: 499-502.
21. Moser HW, Moser AB, Naidu S, Bergin A. Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991; 13: 254-261.
22. El-Deiry SS, Naidu S, Blevins LS, Ladenson PW. Assessment of adrenal function in women heterozygous for adrenoleukodystrophy. J Clin Endocrinol Metab 1997; 82: 856-860.
23. Reinecke CJ, Knoll DP, Pretorius PJ, Steyn HS, Simpson RH. The correlation between biochemical and histopathological findings in adrenoleukodystrophy. J Neurol Sci 1985; 70: 21-38.
24. Boue J, Oberle I, Heilig R, Mandel JL, Moser A, Moser H, et al. First trimester prenatal diagnosis of adrenoleukodystrophy by determination of very long chain fatty acid levels and by linkage analysis to a DNA probe. Hum Genet 1985; 69: 272-274.
25. Aubourg PR, Sack GH Jr, Meyers DA, Lease JJ, Moser HW. Linkage of adrenoleukodystrophy to a polymorphic DNA probe. Ann Neurol 1987; 21: 349-352 .
26. Seneca S, Lissens W. DNA diagnosis of X-linked adrenoleukodystrophy. J Inherit Metab Dis 1995; 18 (suppl. 1): 34-44 .
27. Kumar AJ, Rosenbaum AE, Naidu S, Wener L. Citrin CM, Lindenberg R, et al. Adrenoleukodystrophy: correlating MR imaging with CT. Radiology 1987; 165: 497-504.
28. Young RSK, Ramer JC. Towfight J, Weidner W, Lehman R, Moser HW. Adrenoleukodystrophy: unusual computed tomographic appearance. Arch Neurol 1982; 39: 782-783.
29. Romero C, Dietemann JL, Kurtz D, Bataillard M, Christmann D. Adrenoleukodystrophy. Value of contrast-enhanced MR imaging. J Neuroradiol 1990; 17: 267-276.
30. Kruse B, Barker PB, van Zijl PC, Duyn JH, Moonen CT, Moser HW. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 1994; 36: 595-608.
31. Al-Essa M, Bakheet S, Al-Shamsan L, Patay Z, Powe J, Ozand PT. 18 FDG PET scan and MRI brain scan in type IV 3-methylglutaconic aciduria. Brain Dev 1999; 21: 24-29.
32. Al-Essa M, Bakheet S, Patay Z, Al-Watban J, Powe J, Joshi S, et al. 18Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in glutaric aciduria type 1: clinical and MRI correlations. Brain Dev 1998; 20: 295-301.
33. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP Jr. Adrenoleukodystrophy: A clinical and pathological study of 17 cases. Arch Neurol 1975; 33: 577-591.
34. Battaglia A, Harden A, Pampiglione G, Walsh PJ. Adrenoleukodystrophy: neurophysiological aspects. J Neurol Neurosurg Psychiatr 1981; 44: 781-785.
35. Shimizu H, Moser HW, Naidu S. Auditory brainstem response and audiologic findings in adrenoleukodystrophy: its variant and carrier. Otolaryngol Head Neck Surg 1988; 98: 215-220.
36. Krivit W, Lockman L, Watkins PA, Hirsch J, Shapiro EG. The future for treatment by bone marrow transplantation for adrenoleukodystrophy. metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis 1995; 18: 398-412.
37. Tobimatsu S, Fukui R, Kato M, Kobayashi T, Kuroiwa Y. Multimodality evoked potentials in patients and carriers with adrenoleukodystrophy and adrenomyeloneuropathy. Electroencephalogr Clin Neurophysiol 1985; 62: 18-24.
38. Wanders RJ, van Roermund CW, Van Wijland MJ, Schutgens RB, van den Bosch H, Schram AW, et al. Direct demonstration that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem Biophys Res Comm 1988; 153: 618-624.
39. Aubourg P, Mosser J, Douar AM, Sarde CO, Lopez J. Mandel JL. Adrenoleukodystrophy gene: unexpected homology to a protein involved in peroxisome biogenesis. Biochimie 1993; 75: 293-302.
40. Krasemann EW, Meier V, Korenke GC, Hunneman DH, Hanefeld F. Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy. Hum Genet 1996; 97: 194-197.
41. Dodd A, Rowland SA, Hawkes SL, Kennedy MA, Love DR. Mutations in the adrenoleukodystrophy gene. Hum Mutat 1997; 9: 500-511.
42. Aubourg PR, Sack GH Jr, Moser HW. Frequent alteration of visual pigment genes in adrenoleukodystrophy. Am J Hum Genet 1988; 42: 408-413.
43. Sack GH Jr, Raven MB, Moser HW. Color vision defects in adrenoleukodystrophy. Am J Hum Genet 1989; 44: 794-798.
44. Van Duyn MA, Moser AE, Brown FR 3d, Sacktor N, Liu A. Moser HW. The design of a diet restricted in saturated very long-chain fatty acids: therapeutic application in adrenoleukodystrophy. Am J Clin Nutr 1984; 140: 277-284.
45. Brown FR 3d, Van Duyn MA, Moser AB, Schulman JD, Rizzo WB, Snyder RD, et al. Adrenoleukodystrophy; effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids Johns Hopkins Med J 1982; 151: 164-172.
46. Rizzo WB, Phillips MW, Dammann AL, Leshner RT, Jennings SS, Avigan J, et al. Adrenoleukodystrophy : dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987; 21: 232-239 .
47. Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft DA, Jensen ME, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989; 39: 1415-1422.
48. Moser HW. Lorenzo oil therapy for adrenoleukodystrophy: a prematurely amplified hope. Ann Neurol 1993; 34: 121-122.
49. Moser HW, Bergin A, Cornblath D. Peroxisomal disorders. Biochem Cell Biol 1991; 69: 463-474.
50. Moser HW, Tutschka PJ, Brown FR 3d, Moser AE, Yeager AM, Singh I, et al. Bone marrow transplant in adrenoleukodystrophy. Neurology 1984; 34: 1410-1417.
51. Aubourg P, Blanche S, Jambaque I, RocchiccioliF, Kalifa G, Naud-Saudreau C, et al. Reversal of early neurologic and neuroradiologic manifestation of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322: 1860-1866.
52. Malm G, Ringden O, Anvret M, Von Dobeln U, Hagenfeldt L, Isberg B, et al. Treatment of adrenoleukodystrophy with bone marrow transplantation. Acta Paediatr 1997; 86: 484-492.
53. Naidu S, Bresnan MJ, Griffin D, O'Toole S, Moser HW. Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol 1988; 45: 846-848.
54. Stumpf DA, Hayward A, Haas R, Frost M, Schaumburg HH. Adrenoleukodystrohy: Failure of immunosuppression to prevent neurological progression. Arch Neurol 1981; 38: 48-49.
55. Miike T, Taku K, Tamura T, Ohta J, Ozaki M, Yamamoto C et al. Clinical improvement of adrenoleukodystrophy following intravenous gammaglobuline therapy. Brain Dev 1989; 11: 134-137.
56. Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S. High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatr 1994; 57 (suppl): 69-70.
57. Noel P, Nelson S, Bokulic R, Bagby G Lippton H, Lipscomb G et al Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990; 47: 1023-1029.
58. Alegre ML, Gastaldello K, Abramowicz D, Kinnaert P, Vereerstraeten P, De Pauw L et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991; 52: 674-679.
59. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adrenoleukodystrophy: cells, effector molecules, and pathogenic implications. J Neuropathol Exp Neurol 1992; 5: 630-643.
60. Murphy JV, Marquardt KM, Moser HW, Van Duyn MA. Treatment of adrenoleukodystrophy by diet and plasmapheresis. Ann Neurol 1982; 12: 220 (Abstract 72).